MarginsXMarginsX
Home › Markets › Health Care › KMDA

Kamada Ltd. (KMDA)

KMDA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$8.11
+0.25% on the day
Market cap
$468.0M
Small cap
Revenue · 2025
$180.5M
+12.1% on 2024
Net income · 2025
$20.2M
11.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1567529/000121390026025934/0001213900-26-025934-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerKMDA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIsrael
IPO year2013
SEC CIK0001567529
SEC industry codePharmaceutical Preparations
Incorporated inIsrael

Financials · 2025

LineValue
Revenue$180.5M
Net income$20.2M
Operating income$26.2M
Net margin11.2%
Operating margin14.5%
Revenue growth+12.1%
Cash$75.5M
Total assets$378.7M
P/E (computed)23.2×
P/S (computed)2.6×

Warning signs

Cash runway
Cash-flow positive
$75.5M cash at December 31, 2025
Share count, 1 year
+0.3%
2024-12-31 to 2025-12-31 · +28.7% over 3 years
Going-concern doubt
No
20-F filed March 11, 2026
Insider net buying, 12 months
-$1.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-03-11
Cash and burn$75.5M cash; operating cash flow $6.4M a quarter.Report 2025-12-31
Shares outstanding57,686,056 (2025-12-31); 57,505,031 a year earlier; 44,832,843 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-09-09
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKost Forer Gabbay & Kasierer, Tel Aviv, IsraelPCAOB Form AP 2026-04-11
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $1.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$180.5M$20.2M$25.5M$75.5MNo debt tags$180.5M20-F 2026-03-11
FY 2024
2024-12-31
$161.0M$14.5M$47.6M$78.4MNo debt tags$161.0M20-F 2026-03-11
FY 2023
2023-12-31
$142.5M$8.3M$4.3M$55.6MNo debt tags$142.5M20-F 2026-03-11
FY 2022
2022-12-31
$129.3M-$2.3M$28.6M$34.3M$4.4M$129.3M20-F 2025-03-05
FY 2021
2021-12-31
$103.6M-$2.2M-$8.8M$18.6M$3.8M$103.6M20-F 2024-03-06
FY 2020
2020-12-31
$133.2M$17.1M$19.1M$70.2M$238K$133.2M20-F 2023-03-15
FY 2019
2019-12-31
$127.2M$22.3M$27.6M$42.7M$489K$127.2M20-F 2022-03-15
FY 2018
2018-12-31
$114.5M$22.3M$10.5M$18.1M$452K$114.5M20-F 2021-02-24

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
REGISTRATION STATEMENT
F-32026-09-09
Latest annual report
ANNUAL REPORT
20-F2026-03-11
Latest quarterly / interim
REPORT OF FOREIGN PRIVATE ISSUER
6-K2026-11-09

Source: SEC EDGAR submissions feed, 539 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+11.9%
1 month+5.2%
3 months+11.4%
Year to date+14.6%
1 year+14.3%
From 52-week high-13.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
LYELLyell Immunopharma Inc.$14.65+2.45%$469.0M
OCSOculis Holding AG$7.63-0.13%$469.9M
AQSTAquestive Therapeutics Inc.$3.76-3.84%$472.6M
STTKShattuck Labs Inc.$4.66+0.21%$474.6M
PHATPhathom Pharmaceuticals Inc.$5.88-2.97%$478.0M
NGNENeurogene Inc. Common Stock$23.30-2.63%$482.3M
CAPRCapricor Therapeutics Inc.$8.30-12.91%$482.6M
OVIDOvid Therapeutics Inc.$2.40-5.51%$453.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier